Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

By J. Mendelsohn, J. Baselga. Journal of Clinical Oncology, 2003

1,295 citations recorded by the source corpus.

Subfields: Safety Research

View Paper: https://www.semanticscholar.org/paper/954b1f74810843aff23c76dcd52307ab95df4683

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Safety Research

1. M. Lacouture
2. C. Blobel
3. J. Baselga

Citations in the corpus

• ADAMs: key components in EGFR signalling and development (2005, background): “As the EGFR pathway is a validated target for anti-cancer drug”
• Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal (2013, neutral): “8A) (26, 27).”
• GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands (2015, background): “The dysregulation of EGFR has been observed in a wide range of cancers (2, 3) and implicated in tumor progression and resistance to radiationinduced cell death (4).”
• Mechanisms of cutaneous toxicities to EGFR inhibitors (2006, background): “Pharmacologically mediated blockade of EGFR results in growth arrest and apoptosis in cells that are dependent on EGFR for survival, through the inhibition of downstream pathways such as the MAPK (mitogen-activated protein kinase) pathway, the PI3K (phosphatidylinositol 3-kinase)–Akt pathway, the st”
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009, background): “jpg" NDATA ITEM> ]> Members of the epidermal growth factor family of transmembrane receptors (Erbb family) are potent mediators of normal cell growth and developmen”
• Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. (2005, background): “These two patients exhibited unfavorable immunohistochemical profiles (ie, weak [1 ] p-Akt and positive [1 /2 ] p-Erk).”
• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. (2005, background): “Mutations in non–small-cell lung cancers have been found in [1] epidermal growth factor receptor (EGFR) and ErbB2, [2] PIK3CA, [3] K-ras, and [4] BRAF.”
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. (2007, background): “In these patients, the tumor growth is likely to be driven predominantly by the EGFR pathway (6, 7).”
• Comparing antibody and small-molecule therapies for cancer (2006, background): “Therefore, these receptors have been a focus of molecular-targeting therap”
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. (2005, background): “Perturbations in these cellular signals can lead to malignant transformation, and the correlation between EGFR and cancer has been firmly established (Arteaga, 2003; Mendelsohn and Baselga, 2003).”